Corcept Therapeutics Incorporated
CORT
Rank in Stocks
#1819
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Share Price
$109.25
Last synced: 2026-10-16
Market Cap
$11.81B
Change (1 day)
-3.64%
Change (1 year)
38.83%
Country
US
Trade Corcept Therapeutics Incorporated (CORT)
Category
Healthcare
Operating Margin for Corcept Therapeutics Incorporated (CORT)
Operating Margin as of October 2026 TTM: 0.77%
According to Corcept Therapeutics Incorporated latest financial reports and stock price the company's current Operating Margin (TTM) is 0.77%. At the end of 2023 the company had an Operating Margin of 22.24%.
Operating Margin history for Corcept Therapeutics Incorporated from 2001 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.77% | -96.21% |
| 2024 | 20.29% | -8.77% |
| 2023 | 22.24% | -20.66% |
| 2022 | 28.03% | -17.58% |
| 2021 | 34.01% | -6.13% |
| 2020 | 36.23% | -0.49% |
| 2019 | 36.41% | 2.22% |
| 2018 | 35.62% | 7.29% |
| 2017 | 33.20% | 165.18% |
| 2016 | 12.52% | -282.77% |
| 2015 | -6.85% | -93.41% |
| 2014 | -104.02% | -74.04% |
| 2013 | -400.66% | -63.47% |
| 2012 | -1,096.82% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | -100.00% |
| 2009 | -69,827.59% | 641.22% |
| 2008 | -9,420.57% | 270.82% |
| 2007 | -2,540.46% | -70.80% |
| 2006 | -8,701.36% | 0.00% |
| 2005 | 0.00% | 0.00% |
| 2004 | 0.00% | 0.00% |
| 2003 | 0.00% | 0.00% |
| 2002 | 0.00% | 0.00% |
| 2001 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 62.34% | -19.04% |
US
|
|
| 0.00% | - |
SE
|
|
| 0.00% | - |
FR
|
|
| 0.00% | - |
IT
|
|
| 29.76% | -61.35% |
HK
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.